Company Name: Cardiol Therapeutics Inc ISIN: CA14161Y2006   Reason for the research: Update Recommendation: BUY from: 22.11.2024 Target price: USD8.50 Target price on sight of: 12 months Last rating change: - Analyst: Christian Orquera First Berlin Equity Research has published a research update on Cardiol Therapeutics Inc. (ISI [ … ]

Company Name: Cardiol Therapeutics Inc ISIN: CA14161Y2006   Reason for the research: Update Recommendation: Buy from: 28.10.2024 Target price: USD8.50 Target price on sight of: 12 months Last rating change: - Analyst: Christian Orquera First Berlin Equity Research has published a research update on Cardiol Therapeutics Inc. (ISI [ … ]

First Berlin Equity Research has published a research update on Cardiol Therapeutics Inc. (ISIN: CA14161Y2006). Analyst Christian Orquera reiterated his BUY rating and increased the price target from USD 3.60 to USD 8.50. Abstract: Cardiol Therapeutics (Cardiol) announced excellent topline data for its phase II open-label pilot US study (MAvERI [ … ]

First Berlin Equity Research has published a research update on Cardiol Therapeutics Inc. (ISIN: CA14161Y2006). Analyst Christian Orquera reiterated his BUY rating and maintained his USD 3.60 price target. Abstract: Cardiol Therapeutics (Cardiol) announced that the FDA has granted Orphan Drug Designation (ODD) in the US for its lead drug candid [ … ]

First Berlin Equity Research has published a research update on Cardiol Therapeutics Inc. (ISIN: CA14161Y2006). Analyst Christian Orquera reiterated his BUY rating and maintained his USD 3.60 price target. Abstract: Cardiol Therapeutics (Cardiol) has completed >50% of patient recruitment for CardiolRx's two lead indications, acute myocarditi [ … ]